Archive for the ‘Cell Therapy’ Category

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/2v6lkd/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2012, and projected to 2022. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 287 of these are profiled in part II of the report along with tabulation of 273 alliances. Of these companies, 158 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 55 Tables and 12 Figures. The bibliography contains 1,050 selected references, which are cited in the text.

Key Topics Covered:

See more here:
Research and Markets: Cell Therapy - Technologies, Markets and Companies - Updated 2013 with New Companies and Profiles

WALTHAM, Mass.--(BUSINESS WIRE)--

ViaCord, PerkinElmers family cord blood and tissue preservation business, is collaborating with the Center for International Blood and Marrow Transplant Research (CIBMTR) to collect, maintain and publish research from ViaCords cord blood stem cell transplants. This collaboration will expand knowledge of cord blood-derived stem cell applications throughout the medical and research community. To date, CIBMTRs large network of transplant centers has resulted in the development of a clinical database of more than 30,000 cord blood transplant recipients for clinical decision-making, use in studies, and other research purposes with the goal of making a profound impact on the survival of cord blood transplant patients around the world. CIBMTR will work directly with ViaCord to collect and analyze data to better understand the quality and any outcome metrics of ViaCords released cord blood stem cell units as well as how the units are being used.

Collaborating with CIBMTR, which has established the industry standard for collecting data around hematopoietic cellular therapy and regenerative medicine, allows us to simultaneously gain insights into the effectiveness of the cord blood stem cell units we have released for use as well as outcomes from their clinical application, said Morey Kraus, Chief Scientific Officer, ViaCord. We are then able to incorporate data from our transplanted units into the larger database, which may be accessed for other CIBMTR studies by the medical and scientific community to further their research and understanding of cord blood stem cells.

ViaCord is working with CIBMTR to collect and publish data as well as identify outcomes unique to related or autologous (stem cells from the same patient) transplants. The collaboration will also enable the analysis of umbilical cord units released for potential future use in autologous cell therapy and regenerative medicine clinical trials, including Cerebral Palsy, Type 1 Diabetes and others.

The science of cord blood and cord tissue stem cells is growing at a rapid pace, said J. Douglas Rizzo, M.D., M.S., Associate Scientific Director, CIBMTR. We are excited to collaborate with ViaCord to provide data and analytic expertise that will assist the development of the field through research.

ViaCord's family cord blood banking services currently offers expectant families the opportunity to preserve their baby's umbilical cord blood for potential medical use by the child or a related family member. Families are also preserving their babys umbilical cord tissue because research suggests that one day these special cells may have the potential to treat medical conditions that are untreatable today. ViaCord has preserved the umbilical cord blood of more than 300,000 newborns. Twenty years ago, cord blood stem cells were used to treat just one disease, Fanconi's anemia. Today, cord blood stem cells have been used in the treatment of nearly 80 diseases, including cancers, certain blood disorders and immunodeficiencies. Please visit http://www.viacord.com for more information.

Factors Affecting Future Performance This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) fluctuations in the global economic and political environments; (3) our failure to introduce new products in a timely manner; (4) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (5) our failure to adequately protect our intellectual property; (6) the loss of any of our licenses or licensed rights; (7) our ability to compete effectively; (8) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (9) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (10) disruptions in the supply of raw materials and supplies; (11) the manufacture and sale of products exposing us to product liability claims; (12) our failure to maintain compliance with applicable government regulations; (13) regulatory changes; (14) our failure to comply with healthcare industry regulations; (15) economic, political and other risks associated with foreign operations; (16) our ability to retain key personnel; (17) significant disruption in our information technology systems; (18) our ability to obtain future financing; (19) restrictions in our credit agreements; (20) our ability to realize the full value of our intangible assets; (21) significant fluctuations in our stock price; (22) reduction or elimination of dividends on our common stock; and (23) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About the Center for International Blood and Marrow Transplant Research(CIBMTR) A combined research program of the National Marrow Donor Program and the Medical College of Wisconsin, the CIBMTR facilitates critical, cutting-edge research that has led to increased survival and an enriched quality of life for thousands of patients. The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation and cellular therapy research worldwide. The prospective and observational research is accomplished through scientific and statistical expertise, a large network of transplant centers and clinical database of more than 350,000 transplant recipients.

About PerkinElmer, Inc. PerkinElmer, Inc. is a global leader focused on improving the health and safety of people and the environment. The company reported revenue of approximately $2.1 billion in 2012, has about 7,500 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at http://www.perkinelmer.com.

Original post:
ViaCord® to Advance Cord Blood Stem Cell Therapy Research through Collaboration with the Center for International ...

Public release date: 28-Apr-2013 [ | E-mail | Share ]

Contact: Hilary Glover hilary.glover@biomedcentral.com 44-020-319-22370 BioMed Central

Injection of human stem cells into mice with tumors slowed down tumor growth, finds research published in BioMed Central's open access journal Stem Cell Research & Therapy. Human mesenchymal stem cells (MSC), isolated from bone marrow, caused changes in blood vessels supplying the tumor, and it is this modification of blood supply which seems to impact tumor growth.

The use of stem cells in treating cancer has been controversial, with some studies finding that stem cells force tumors to enter programmed cell death. However other studies find that stem cells actually promote tumor growth by inducing infiltration of new blood vessels. In attempting to sort out this puzzle researchers from INSERM groups at Universit Joseph Fourier in collaboration with CHU de Grenoble investigated the impact of MSC on already established subcutaneous or lung metastasis in mice.

For both the subcutaneous and lung tumors, injection of MSC reduced cell division, consequently slowing the rate of tumor growth. Part of the mode of action of stem cells therefore appears to be due to with angiogenesis, but the mechanism behind this is still unclear.

Claire Rome who led this study explained, "We found that MSC altered vasculature inside the tumor - although new blood vessels were generated, overall they were longer and fewer than in untreated tumors. This could be restricting the oxygen and nutrients to the tumor, limiting cell division." She continued, "Our study confirms others which propose that stem cells, in particular MSC, might be one way forwards in treating cancer."

Commenting on this study Celia Gomes, from the University of Coimbra, said, "One of the interesting questions this study raises is when MSC promote tumor growth and when they restrict it. The answer seems to be timing this study looks at already established tumors, while others, which find that MSC increase growth, tend to be investigating new tumors. This is a first step in the path to identifying exactly which patients might benefit from stem cell therapy and who will not."

###

Media Contact

Dr Hilary Glover Scientific Press Officer, BioMed Central Tel: +44 (0) 20 3192 2370 Mob: +44 (0) 778 698 1967 Email: hilary.glover@biomedcentral.com

Visit link:
Clarifying the effect of stem cell therapy on cancer

MS Stem Cell Therapy - Part 1
Over the last decade a Canadian team has been working on a ground breaking stem cell therapy their research has yet to be published, but the patients who hav...

By: GlobalToronto

See the original post:
MS Stem Cell Therapy - Part 1 - Video

NEW YORK, April 24, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

http://www.reportlinker.com/p01075729/Stem-Cell-Therapy-Market-in-Asia-Pacific-to-2018---Commercialization-Supported-by-Favorable-Government-Policies-Strong-Pipeline-and-Increased-Licensing-Activity.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity". The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals' JR-031 (2014) in Japan and FCB Pharmicell's Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

- Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore - In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. - Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. - Key drivers and restraints that have a significant impact on the market. - Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost - Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

Read more:
Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies ...

Joshua Aquino plays piano for mom Kris. File photo

MANILA, Philippines Host-actress Kris Aquino explained that one of the reasons she is going on temporary leave from showbiz is because she wanted her eldest son, Josh, to undergo stem cell therapy.

During her morning talk show on ABS-CBN, Kris TV, on Tuesday, Aquino said she is considering three options for the treatment of Josh, who is a special child.

The first option is for Josh to undergo treatment in Europe, where live animal stem cells are used.

Kasi meron akong mga friends na yung mga anak nila underwent stem cell therapy and yung condition nila is just like Josh. They had special children, Aquino explained to comedienne Melai Cantiveros, her guest co-host on Kris TV.

Kasi sobrang laki yung naging improvement. So tomorrow, Melai, meron kaming appointment kay Dr. Rex Gloria, who is involved with one of those hospitals sa Europe na gumagawa nito, she added.

Aquino said her second option is to avail of a new treatment in Singapore, which involves the use of fat-derived human stem cells.

Meron daw sa Singapore na kinukuha daw sa nanay yung stem cell. Parang manggagaling sa fat ng nanay, kasi yung fat ng nanay ang pinaka-highly concentrated yung stem cell, doon, she said. So kukunin either sa hita daw o sa tiyan ng mom, tapos ita-transfer doon sa anak.

Meanwhile, Aquino said her third option is to go to The Medical City in Pasig.

May pangatlo pa being done in Medical City naman now. But that study will be done in July. Yun naman, galing sa bone marrow. Medyo masakit daw yun talaga kasi imagine, bone marrow extraction, she said.

Read more:
Kris wants stem cell therapy for son Josh

Kris Aquino will try anything -- even the new stem cell therapy technology in Singapore to help eldest son Josh cope with his Attention Deficit Hyperactivity Disorder (ADHD) condition. Read related story: Kris In Search For Joshuas House

"Meron akong mga friends na yung mga anak nila underwent stem cell therapy. And yung condition nila is just like Josh's and they're special children. Sobrang laki kasi yung naging improvement," Kris said on "KrisTV" on Tuesday, April 23.

Physical exam

Kris said Josh will have a physical exam on April 24 to check if he is fit to undergo stem cell therapy.

"Hindi mo naman matatanggi sa akin na anything to improve my son kasi ngayon na-achieve namin yung physical improvement. Kasi di ba naka-lose nga siya ng 120 pounds? So ngayon we have the means naman, bakit hindi ko susubukan kung makakatulong ito for him to become more verbal, yung cognitive skills lalong ma-improve?"

She added, "Meron raw sa Singapore na kinukuha rin sa nanay, yung stem cell. Manggagaling raw sa fat ng nanay. Kasi yung fat ng nanay ang highly-concentrated ang stem cell. So kukunin either sa tiyan or hita ng nanay then itatransfer sa anak."

ABS-CBN announced that Kris will take a leave from work in June to attend to her sons' needs, including bringing Josh abroad "to advance his developmental progress."

Also read: Kris not resigning, will 'take a leave instead'

Adult Josh

"Iyan ita-try nating lahat kasi it's so hard to believe that this June 4, Josh is turning 18. May adult na akong anak. Ita-try natin ito. Part of the reason why I'm taking a leave is because I want Josh to have these opportunities for medical improvement, lalo na andun na siya sa magandang timbang, magandang health, magandang behavior. So, ita-try namin ito para tuloy-tuloy ang progress ng anak ko," she said.

Read the original post:
Kris wants Josh to undergo stem cell therapy

By Christian V. Esguerra Philippine Daily Inquirer

Former Senator Ernesto Maceda. FILE PHOTO

AGOO, La Union, PhilippinesThanks to the wonders of science, the oldest candidate in the May 13 senatorial election has managed to keep up with the grueling campaign.

So far, 78-year-old former Senate President Ernesto Maceda said Friday, he has not gotten sick despite a tough campaign schedule that usually requires him to travel from one province to anotherall thanks to the stem cell therapy he got for P600,000 at a medical facility in Germany in March last year.

I am now convinced that my stem cell therapy is effective and thats the reason why Ive been able to keep up with the rigorous campaign schedule, he told reporters before climbing the campaign stage at the Eriguel compound.

Maceda said the therapy was relatively cheap, noting that it would have cost him around P2.5 million if he had it in the Philippines. And it was worth it, he said.

I feel 20 years younger, he said.

Maceda joined a growing list of aging politicians who have resorted to stem cell therapy. They include Senate President Juan Ponce Enrile, 89, and former President Joseph Estrada, who celebrated his 76th birthday Friday.

Responding to a question by a TV reporter, Vice President Jejomar Binay said he does not need it yet.

The UNA campaign schedule is no walk in the park.

Read more from the original source:
Maceda attributes stamina to stem cell therapy, malunggay pills

Vatican hosts conference on advancements in stem cell therapy
http://en.romereports.com.

By: romereports

Read more from the original source:
Vatican hosts conference on advancements in stem cell therapy - Video

Doctors, Patients Speak on Personal Experiences Vatican City, April 11, 2013 (Zenit.org) Junno Arocho Esteves | 716 hits

During todays first session of the Second International Vatican Adult Stem Cell Conference, scientists, doctors and patients had an opportunity to share not only the advances in adult stem cell research, but also the potential it has to transform modern day health care.

The ethical debate on the use of embryonic stem cells has, according to Dr. Robin Smith, stifled the advances made in adult stem cells, which are derived from adult tissue samples. Dr. Smith serves as president of the Stem for Life Foundation as well as CEO of NeoStem, a leading developer in cellular therapy.

Stem Cell Therapy, especially using cultivated adult stem cells , can be used to regenerate dying tissue in the body of a person suffering debilitating diseases, such as Alzheimers, Parkinsons, or Multiple Sclerosis (MS).

In November 2001, we kicked of the first Stem Cell Conference. Since then, the entire world has awakened.

By improving the clinical outcomes, we can save hundreds of millions of lives, she said. We're not talking about medications, she continued. Were talking about repairing the heart with adult stem cells. Re-inserting these cells into a damaged organ is turning back the clock. In just 17 months, we have seen stunning advancements in leukemia treatments.

The work in stem cell research has only begun to be understood. The last conference did not have panels that discussed the benefits of cellular therapy on MS and diabetes. Dr. Smith stated that in the United States, $245 billion is spent on managing diabetes, which can cause blindness, stroke and amputations which is only getting worse.

Cellular therapy has the potential to rewrite the history of this disease, she said. Adult stem cells is something we can all agree upon; they are ethically pure. We can grasp whats inside of us and introduce them into the body.

The purpose of the conference, she concluded, was meant to inspire change and to promote the truth and promise behind stem cell science. We hope to show that you no longer have to choose between science and faith.

In Search of Hope

Follow this link:
Vatican Conference Hopes to Promote Truth on Adult Stem Cell Therapy

Stem Cell Therapy for Pets -- Taylor Before After
Amazing before and after footage of Taylor, a 7 year old dog who received stem cell therapy for arthritis in her hips, knees and ankles. For more information...

By: NewmanVets

See original here:
Stem Cell Therapy for Pets -- Taylor Before

Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Could stand with calipers and wal...

By: neurogenbsi

More here:
Stem Cell Therapy Treatment Improvements in Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

By Tina G. Santos Philippine Daily Inquirer

MANILA, PhilippinesStem cell therapy at spa centers and salons? Watch out, government agents are coming.

Health Secretary Enrique Ona says no clinic or hospital in the Philippines can offer stem cell therapy without accreditation from the Department of Health (DOH).

Speaking to reporters last week, Ona noted that while many centers are advertising stem cell therapy treatment, none of them have the approval of the health department.

As of now we have not accredited any clinic or even hospital offering stem cell therapy yet, Ona said.

Admitting that the DOH doesnt have the police power to close down erring health centers, Ona said the department would coordinate with other governmental agencies like the Department of Trade and Industry (DTI) and local governments to prevent spas and salons from offering stem cell treatment.

We will issue a warning for them to stop [doing stem cell therapy]. But if they continue despite warnings from us, thats when we will move to close them down, Ona said.

Stem cell therapy and treatment, which are becoming popular here and abroad, are medical procedures that deal with ailments by replacing malignant cells with healthy cells.

Only medical doctors with the right training can perform stem cell treatment.

Cosmetic purposes

Continue reading here:
Spas, salons warned on stem cell therapy

Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma After Stem Cell Therapy 1) Ankle dorsiflexion movements are possible now. 2) He is able ...

By: neurogenbsi

Read the original post:
Stem Cell Therapy Treatment for Spinal Cord Injury by Dr Alok Sharma - Video

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma

By: neurogenbsi

See original here:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma - Video

Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India

By: neurogenbsi

View original post here:
Stem Cell Therapy Treatment for Autism by Dr Alok Sharma Mumbai India - Video

By: Azer N. Parrocha, Philippine News Agency March 28, 2013 3:16 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines - Although guidelines for stem cell therapy in the country have already been released, the Department of Health (DOH) on Wednesday reminded the public that hospitals performing the treatment are as of the moment, not accredited.

Health Secretary Enrique Ona, in a press conference, explained that for a hospital or clinic to be considered accredited, a years worth of tests and studies have to be done to prove that the procedure is indeed safe and effective.

I hope the general public understands that these stem cells, although called innovative (form of treatment) is not standard and should not be advertised as though it is already an accepted form of treatment, Ona said.

Ona explained that the DOH still continues to look on the capacity of the treatment and will make sure that the stem cells used for procedure are accepted as protocol.

Stem cells like those coming from embryos or animals which are restricted will also be looked into by the DOH to see if there are any hospitals or clinics that do not abide by the administrative order.

If the protocol is accepted, report of results should be evaluated, he said. They are evaluated about a year to see if their claim is effective [and if it is] it will be validated.

At present, there are no hospitals or clinics completely accredited for the stem cell therapy yet. Given that, certain processes must be followed before doctors are allowed to use the treatment.

I cannot see a so-called clinic yet certifying that there is a process that is very effective, Ona explained. We have to see the type of stem cell, the type of claim they have.

Read the original here:
Hospitals performing stem cell therapy are yet to be accredited – DOH

Stem Cell Therapy Cures Paralyzed Vet

By: TheVideOHM

More:
Stem Cell Therapy Cures Paralyzed Vet - Video

By Amads Ma. Guerrero Philippine Daily Inquirer

INFORMATION booth

You feel like you have entered an attractive boutique hotel in miniature; everything is neat, clean, almost spotless and sparkling.

This is the Asian Aesthetic Center in Katipunan Avenue, Quezon City (contact number: 7099565) across the Ateneo de Manila. The equipment is state-of-the-art, and there are two main wings: The Dermatology Wing and the Surgical Wing.

In the Dermatology Wing we have a Laser Room, Slimming Room, a Wellness Room and a Facial Treatment Room. The Surgical Room was what interested me mostbut only as a writer and not personally, because my cells are not dysfunctional (to my knowledge!).

Unfortunately, colleague Neilsen and I could not enter the Surgical Wing because a procedure was under way. In this wing, we were told, is a stem cell laboratory unit with the stem cell extractor and activator machines, and a recovery room, along with other amenities.

The clinic is cozy and family-run, you might say. It is headed by Dr. Amy B. Tinaza, a cosmetic surgeon and a stem cell specialist, and her partner (professional as well as personal) Dr. Jomar S. Tinaza, chief facial plastic surgeon and her husband. And the centers PR is a sister in law, Charlotte Tinaza.

The Tinaza couple head the Stem Cell Therapy Team, and there are also Medical, Surgical, Specialist and After-Care Teams.

So why did she (Dr. Amy) choose to be a stem cell specialist? Although stem cell therapy is at an early stage, I believe it is the future of medicine, she replies.

The centers stem cell therapy is the Autologous Fat Stem Cell, in which the stem cell is from the fat cells of the same patient, and transferred back to the patient once the stem cell is activated.

Read the rest here:
Stem cell therapy –how profitable?

Stem Cell Therapy For Pets - Kye Before After
Amazing before and after footage of Kye, an 11 year old lab who received stem cell therapy for his arthritis. For more information about stem cell therapy fo...

By: NewmanVets

See the original post here:
Stem Cell Therapy For Pets - Kye Before

Stem cell therapy has been found useful in over 60 per cent of the patients due for liver transplant, as per a paper submitted by doctors at Sir Ganga Ram Hospital in Delhi recently. Not only is the treatment less cumbersome and risky, its cost is also comparatively very reasonable.

According to the papers principal author and chairman of the Department of Gastroenterology and Liver Diseases at the Hospital, Dr. Anil Arora, a large number of patients requiring liver transplantation cannot afford it for two reasons cost and donor availability.

A living donor is needed in such plantation cases with a matching blood group and he or she also has to be a family member or a first or second degree relative. They have to donate the liver. Since Rs.20 lakh is the average cost of liver transplantation, a majority of liver cirrhosis patients can not afford it. Many times they also do not have a donor, he said.

In view of the logistical problems faced by such patients, Dr. Arora said: We started looking at the feasibility of alternative methods like using reserve cells in the body called stem cells for such treatment as it costs even less than Rs.50,000. Some of these cells can be mobilised from the bone marrow as it has the capacity to regenerate the cells. So we stimulate the bone marrow by an injection.

This injection is given for five days and it mobilises the bone marrow and some of the cells. They then come into the blood circulation. In the study we tried to filter these cells from the blood marrow using a specialised filtering machine and the concentrate of these cells. About 5 ml to 10 ml of the blood containing these concentrated group of cells was then injected into the hepatic artery, which supplies blood to the liver, explained Dr. Arora. He said this process was carried out by a number of different mechanisms and it proved quite successful. We started about two years ago and finished last year. Then these patients were followed up for another one year and we were happy to see a significant proportion of the patients having substantial improvement in the liver functions as assessed by a score called Child score.

Dr. Arora said, All patients tolerated the treatment well without any side effects. Of the 10 patients, six to seven benefited. So we believe that more frequent administration of the stem cells in large number might have a more beneficial impact.

While the study by the Sir Ganga Ram Hospital team was published this year and was approved by the Department of Biotechnology and Ministry of Science and Technology, Government of India, Dr. Arora said there is also other published data now which calls for stimulating the bone marrow and letting the cells automatically go into the liver. By this, he said, you avoid filtering and putting the blood with the stem cells into the liver. This is also equally beneficial.

Dr. Arora said stem cell therapy might act as a bridge for liver transplant and can provide some time to the patients to arrange for treatment. But just like a damaged car tyre, he said, a damaged liver after minor repairs has to be replaced. However, if a person stops taking liquor or if the therapy goes on well, then a patient can lead a healthy life for many more years.

Read the original post:
Stem cell therapy is new hope for liver transplant patients

NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company's contract development and manufacturing ("CDMO") subsidiary, Progenitor Cell Therapy ("PCT"), has launched a new service offering, using a custom developed Internet/Web application to further its position as a technology leader for cell therapy. The new service, an automated software system called "PCTFORME.COM", resides in a highly secure, cloud based computing environment, available 24/7, and serves to enhance PCT's service offering to its growing client base. This service has been launched for a major client and is now available for all of PCT's existing and future stem cell clients.

PCTFORME allows PCT's clients to securely access patient details on-line and provides for real time product ordering, processing and retrieval via automated communications between PCT's clients and laboratory staff. The system is expected to significantly enhance communication by enabling easy tracking of current processing, increasing PCT's efficiencies and streamlining the process for the ordering of patient cells for infusion. PCTFORME is HIPAA compliant and built on a proven Microsoft software platform and supporting cloud based hardware infrastructure.

Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, said, "The need to service the demand, in both volume and variety of procedures, continues to grow as PCT serves our client base. The efficiencies gained in order entry, cell product inventory management, and real time procedure result reporting is expected to improve patient care through enhanced communication, control and transparency. In this regard, PCTFORME represents a patient product management breakthrough in stem cell processing."

"As the field of cell therapy continues to emerge, we believe technology will enable us to reduce costs, better service our clients and build scalable operations to be ready for the future when cell therapy becomes standard of care in medical practice," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "Our management is focused on evaluating, developing and incorporating such technologies into our state-of-the-art contract development and manufacturing business to assist our clients, as well as our clinical development subsidiaries, with their cell therapy product development, and in preparation to launch them into the clinic."

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. http://www.neostem.com

About Progenitor Cell Therapy, LLC ("PCT")

PCT, a wholly owned subsidiary of NeoStem, Inc., is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice ("cGMP") development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. http://www.pctcelltherapy.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Read the original post:
NeoStem's Subsidiary, Progenitor Cell Therapy , Launches Web-Based Service for Real-Time Cell Therapy Product Tracking

2013 Stem Cell Therapy #1
Introduction to 11 weeks of stem cell therapy in Delhi with Dr Geeta Shroff.

By: Louis Rowe

Read this article:
2013 Stem Cell Therapy #1 - Video

LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy.

The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council.

The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs.

The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina.

Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition.

"This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans.

"In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is currently a very large unmet medical need."

Shares rose 0.86% to 2.94p at 08:52 Monday.

RD

See more here:
ReNeuron Group wins grants for stem cell therapy development

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Read more here:
Myotonic Muscular Dystrophy Before and After Stem Cell Therapy - Video